Transplantation
Kidney transplantation guidelines, immunosuppression updates, and the latest evidence, curated by the Arab Society of Nephrology and Renal Transplantation (ASNRT).
Browse all news
Explore the full ASNRT newsroom for society announcements, KDIGO guideline updates, AJNT issue releases, and notable developments across the breadth of nephrology.
Latest in this topic
The most recent evidence summaries curated by ASNRT on this topic:
ABO-Incompatible Kidney Transplantation as a Strategic Expansion Tool in Low- and Middle-Income Countries · A perspective on ABO incompatible transplantation. · Comparative Analysis of Lupus Nephritis Guidelines: ACR 2025, EULAR 2025, and Kdigo 2024. · Clazakizumab in the Treatment of Chronic Active Antibody-Mediated Kidney Transplant Rejection: Results from the IMAGINE Phase 3 Randomized, Double-Blind, Placebo-Controlled Study · Vaccinations to Prevent Infections in Adults with CKD and After Kidney Transplantation: A Review · QuantiFERON-CMV Cell-Mediated Immunity to Predict Post-Prophylaxis CMV Disease in D+/R- Kidney Transplant Recipients (Phase 3 Letermovir vs Valganciclovir Trial) · Systematic Review of Kidney Transplant Outcomes in Monoclonal Ig Deposition Disease. · Updates on Kidney Transplantation From the World Transplant Congress 2025 · Replacing Mycophenolate Mofetil by Everolimus to Increase Vaccine Immunogenicity in Kidney Transplant Recipients: A Randomized Controlled Trial · Dual costimulation blockade with the CD154-specific fusion protein dazodalibep and belatacept for prophylaxis of kidney allograft rejection. · Trends in Nephrology: From nihilism to targeted treatment of antibody-mediated rejection · Dual Targeting of B Cell Compartments Using Belatacept and Daratumumab in Highly Sensitized Kidney Transplant Candidates: A Mechanistic Proof-of-Concept Desensitization Trial · Evolving Therapeutic Approaches for Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients · Anti-glomerular basement membrane disease-treatment standard. · Five Years Follow-up of Imlifidase Desensitized Kidney Transplant Recipients. · Immunosuppression in Older Kidney Transplant Recipients: A Randomized Controlled Trial (OPTIMIZE) · A multicenter prospective cohort study evaluating impact of an active delisting strategy to enable kidney transplantation in waitlisted candidates with cPRA >= 99.9% · Self-reported non-adherence to immunosuppressive medication detected by the BAASIS predicts allograft rejections in kidney transplant recipients · Rituximab in antibody-mediated rejection following kidney transplantation: clinical and pathological outcomes · Tocilizumab Treatment for Microvascular Inflammation and Chronic Active Antibody-mediated Rejection in Kidney Transplantation · Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors: A Systematic Review and Individual Participant Data Meta-Analysis · Islet Transplantation. · Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease. · Improving the histologic detection of donor-specific antibody-negative antibody-mediated rejection in kidney transplants. · Immunosuppressive therapy management during sepsis in kidney transplant recipients: a prospective multicenter study · Donor-derived cell-free DNA significantly improves rejection yield in kidney transplant biopsies. · Novel Biomarkers for Rejection in Kidney Transplantation: A Comprehensive Review · Antibody-Mediated Rejection - Treatment Standard · Comparison of outcomes after living and deceased donor kidney transplantation: UK national cohort study. · COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics. · Belatacept Pharmacokinetic Analysis of Belatacept Early Steroid Withdrawal Trial (BEST) to Clinical Outcomes and Compared With Reported BENEFIT and BENEFIT-EXT Pharmacokinetic Analysis. · Management recommendations for kidney transplantation in patients with plasma cell dyscrasia. · Anti-CD38 Daratumumab Treatment of Chronic Active Antibody-Mediated Kidney Allograft Rejection · Outcomes After Kidney Transplantation in Antineutrophil Cytoplasmic Autoantibody-Associated Renal Vasculitis · Infectious disease surveillance and management in clinical xenotransplantation: Experience with the first human porcine kidney transplant. · Defining Relationships Among Tests for Kidney Transplant Antibody-Mediated Rejection · Mini Review Banff 2022 Updated Classification of Renal Allograft Pathology. · Diagnosis, management and treatment of the Alport syndrome - 2024 guideline on behalf of ERKNet, ERA and ESPN · A Randomized Controlled Trial of Intravenous Immunoglobulin vs Standard of Care for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients (VIPAR) · Targeting CD38 in Antibody-Mediated Rejection.